Brian Sweeney, MD
Gastroenterology · Anchorage, AKNPI 1215112065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 24.1% of the total. 2025 is the largest year on record at $1,557, 5.1 times the $304 reported in 2019. Among gastroenterology clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 295 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$595
- Johnson & Johnson$543
- Regeneron Healthcare Solutions, Inc.$329
- Bristol Myers Squibb$311
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,958100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 73 | $1,439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $1,141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 40 | $595 |
| Johnson & Johnson | 32 | $543 |
| Regeneron Healthcare Solutions, Inc. | 13 | $329 |
| Bristol Myers Squibb | 21 | $311 |
| Pfizer | 10 | $279 |
| Madrigal Pharmaceuticals | 10 | $237 |
| Sanofi | 5 | $150 |
| Gilead | 6 | $132 |
| Lilly USA, LLC | 6 | $119 |
| Ardelyx, Inc. | 5 | $92 |
| Boehringer Ingelheim | 4 | $79 |
| Ipsen Biopharmaceuticals, Inc | 3 | $73 |
| Celltrion USA Inc. | 3 | $58 |
| Blueprint Medicines Corporation | 2 | $57 |
| Braintree Laboratories, Inc. | 3 | $56 |
| Redhill Biopharma Inc. | 2 | $46 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Orphalan Inc | 1 | $33 |
| Amgen | 1 | $31 |
| UCB, Inc. | 1 | $28 |
| Merck | 1 | $27 |
| QOL Medical, LLC | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
How this compares
$5,964 in reported general payments places this provider in the 90th percentile of 23 gastroenterology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $277,878 |
| Humira(Cf)Adalimumab | 14 | $190,728 |
| Mesalamine | 17 | $9,927 |
| Dexlansoprazole DrDexlansoprazole | 14 | $6,270 |
| CholestyramineCholestyramine (With Sugar) | 33 | $4,381 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 130 | $2,249 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 122 | $2,113 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,786 |
| Omeprazole | 137 | $1,779 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 20 | $1,385 |
| Esomeprazole Magnesium | 17 | $729 |
| Pantoprazole Sodium | 39 | $460 |
| Amoxicillin | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $1,439 | $190,72814 claims |
| Braintree Laboratories, Inc.Sutab | $56 | $1,78611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 23 gastroenterology providers in Alaska.
Other gastroenterology in Anchorage
- Daryl McClendonAnchorage$6K
- Austin NelsonAnchorage$5K
- Jeffery MolloyAnchorage$5K
- Michelle RandolphAnchorage$1K
- Kavya Kelagere MayigegowdaAnchorage$710
- Martin KaszubowskiAnchorage$646
- Ronald BoisenAnchorage$555
- Geronimo SahagunAnchorage$527
- Saket AmbashtAnchorage$521
- Praveen RoyAnchorage$517
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.